German psychedelic startup Atai targets valuation of $2.3 billion in U.S. IPO
Atai Life Sciences B.V., backed by billionaire investor Peter Thiel, said on Friday it was looking to raise as much as $214.3 million through a U.S. initial public offering, targeting a valuation of about $2.3 billion.